Home » Stocks » I-Mab

I-Mab (IMAB)

Stock Price: $40.67 USD 0.36 (0.89%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 2.87B
Revenue (ttm) 4.29M
Net Income (ttm) -1.45B
Shares Out 70.50M
EPS (ttm) -287.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $40.67
Previous Close $40.31
Change ($) 0.36
Change (%) 0.89%
Day's Open 40.21
Day's Range 39.65 - 41.14
Day's Volume 298,414
52-Week Range 9.30 - 47.46

More Stats

Market Cap 2.87B
Enterprise Value 2.71B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 70.50M
Float n/a
EPS (basic) n/a
EPS (diluted) -287.41
FCF / Share -170.36
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 12,913
Short Ratio 0.05
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 668.98
PB Ratio 11.31
Revenue 4.29M
Operating Income -212.17M
Net Income -1.45B
Free Cash Flow -125.75M
Net Cash 156.11M
Net Cash / Share 2.21
Gross Margin 100.00%
Operating Margin -4,950.58%
Profit Margin -4,950.00%
FCF Margin -2,934.08%
ROA -39.15%
ROE -74.33%
ROIC 7,497.30%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(33.56% upside)
Current: $40.67
Target: 54.32
*Average 12-month USD price target from 6 stock analysts.

Financial Performance

Financial numbers in millions CNY.

Financial Overview

Revenue Growth-44.22%365.39%-
Gross Profit30.0053.7811.56
Operating Income-1,485-455-279
Net Income-1,452-403-298
Shares Outstanding7.386.535.74
Earnings Per Share-2,011.90-617.00-519.30
Operating Cash Flow-868-281-252
Capital Expenditures-12.24-14.41-20.33
Free Cash Flow-880-295-272
Cash & Equivalents1,2251,937679
Total Debt132147213
Net Cash / Debt1,0931,790466
Book Value-2,035-955-300
Numbers in millions CNY, except per-share numbers.

Company Profile

Company Details

Full Name I-Mab
Country China
Employees 185
CEO Hua Qiong Shen

Stock Information

Ticker Symbol IMAB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMAB
IPO Date January 17, 2020


I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. I-Mab has a collaboration agreement with AbbVie Inc. for the development and commercialization of TJC4, an anti-CD47 monoclonal antibody for the treatment of multiple cancers. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.